Modality
Small Molecule
MOA
JAK1i
Target
PD-1
Pathway
Epigenetic
Parkinson's
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Jun 2025
Phase 1Current
NCT08982351
1,129 pts·Parkinson's
2019-12→2025-06·Terminated
1,129 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-179mo agoPh2 Data· Parkinson's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2025-06-17 · 9mo ago
Parkinson's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08982351 | Phase 1/2 | Parkinson's | Terminated | 1129 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Motanaritide | Intellia | Approved | PD-1 |